Reviva Pharmaceuticals Holdings, Inc. received an exception from Nasdaq to continue its listing until March 27, 2026, despite not meeting the $1.00 minimum bid price requirement as of January 20, 2026. The company aims to regain compliance and avoid delisting, which could negatively impact its stock price and capital access.